Cannabis Science, Inc. (OTCBB:CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is thrilled to announce that the company has retained filmmaker Kevin Booth to collaborate on a documentary researching cannabis as a medicine and the truth behind the science of marijuana. Many people know Kevin Booth’s work with the late comedian, Bill Hicks. Kevin produced most of Bill’s CDs and videos that led to the comedian’s own HBO specials and multiple appearances on David Letterman. The story of Kevin’s seventeen-year friendship and working partnership with Bill Hicks was recently explored in a feature length BBC documentary that just ended a year long run of festivals and theatrical screenings. After Bill’s death from pancreatic cancer in 1994, Kevin’s filmmaking took on a political turn and he produced documentaries with talk show host Alex Jones about the incident in Waco, Texas, the American two-party political system, and 9/11. In 2005, Kevin traveled to the UK in order to promote his book titled “Agent of Evolution” about his friendship with Bill Hicks - published by Harper Collins. Several of Kevin’s family members died as a result of alcohol, tobacco, and pharmaceutical use. In 2003 Kevin began investigating the drug war in the United States and produced the documentary “American Drug War: The Last White Hope.” In his investigations, he discovered the United States government considers marijuana more dangerous than crack cocaine or crystal meth. Kevin sought to separate fact from fiction by traveling across the United States, documenting the “fallout” from the War on Drugs and seeking possible solutions and alternatives that have worked elsewhere. Kevin has toured the country, showing his film and lecturing at universities in hope of sparking a meaningful debate. “American Drug War” won best feature documentary at several film festivals from coast to coast and aired continuously on the Showtime network between 2008-2010. During this same time the film was also broadcasted on major networks in Canada, Australia, Poland, Lebanon and South Africa. Kevin recently returned from filming in Juarez Mexico for the follow up to “American Drug War" and is aiming for the sequel’s release later this year.
Kevin Booth’s body of work also include “How Weed Won the West" (a light hearted and humorous look into the California Cannabis culture) “Bill Hicks - Sane Man”, multiple music videos, feature length comedy concerts of Bill Hicks, Fear Factor’s Joe Rogan and groundbreaking comic Doug Stanhope. Kevin’s production of the Hick’s CD “Rant in E Minor” was recently awarded the 11 th best comedy album of all time by Spin magazine competing against Bill Cosby, Chris Rock, Lenny Bruce, Rodney Dangerfield, Eddie Murphy, Sam Kinison, Woody Allen, George Carlin and Richard Pryor just to mention a few. Kevin’s audio productions “Rant in E Minor”, “Arizona Bay” and “Marble Head Johnson” all contain music written and performed by Kevin Booth and Bill Hick who first started playing music together in a high school punk-rock band named STRESS.
Today Kevin runs Sacred Cow Productions dba SCP Enterprises and self distributes through his own sites including SacredCow.com, AmericanDrugWar.com and Amazon. Several of his titles can be found distributed through Warner Brothers and Gravitas VOD that has now broken Booth’s work into the Latin market on both Netflix and ITUNES. As previously announced, Cannabis Science has begun pre-production of its documentary, in which prohibition of marijuana, medicinal benefits of the plant, and international medical marijuana programs will be explored. Booth’s interests and demonstrated experience will be a true asset to Cannabis Science’s endeavors. The documentary will expose audience members to the subject of medical marijuana so that they may gain a better understanding of the research, science, and planning that goes into running Cannabis Science, one of the top marijuana research companies. The documentary will teach viewers about the medicinal benefits for a wide variety of conditions and show them that prohibition is unnecessary. This is clearly a topic for which Kevin Booth will provide great assistance, and Cannabis Science is excited to begin this project.About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. Our formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. Forward Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
